Good MorningEquity markets pulled back from the recent high following the FOMC minutes. The minutes showed that the Fed was worried about the lack of progress on inflation and was ready to hike rates again if necessary. The tone contradicts what the market expected, reducing the odds of a rate cut this year. Without an appreciable improvement in the pace of inflation, the FOMC may have no choice but to keep policy tight if it does not raise rates again.
The market's reaction to the news was light, considering the impact on the economic outlook. The S&P 500's move lower shed less than 1% at the session's low and showed some support at the short-term moving average. Support is due to hopes for earnings growth centered on NVIDIA. NVIDIA is expected to post another blowout quarter driven by AI demand and send its and other AI-centric tech stocks to new highs. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Retail/Wholesale | |
Global-e Online (NASDAQ: GLBE) is succeeding because it offers three things merchants need in one place: eCommerce, direct-to-consumer access, and international expansion. eCommerce is entrenched in our lives and a requirement for any business today. International expansion, specifically cross-bor... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Technology | |
NVIDIA (NASDAQ: NVDA) produced another beat-and-raise quarter that says one thing: as much hype as there is about the AI industry, the market grossly underestimated the impact and importance of NVIDIA semiconductors. The company’s results are so above the consensus estimate they are mind-bog... Read the Full Story |
|
Construction | |
Every once in a while, the market's volatility index (the VIX) goes to an extreme. Whether to the upside or downside, these significant swings bring about massive opportunities for investors who know how to ride the market's volatility cycle. Today, the VIX sits between 11.5% and 13.0%, levels not... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Technology | |
Analog Devices (NASDAQ: ADI) share prices are surging because a trough is in place, and the outlook is robust. The FQ2 results and guidance for FQ3 aren't robust but show markets stronger than expected, and AI supports the pivot back to growth. End-market inventory normalization is expected for se... Read the Full Story |
|
Retail/Wholesale | |
TJX Companies (NYSE: TJX) industry-leading position in off-price retail and quality operations will soon lead its stock price to new heights. Like Walmart (NYSE: WMT), TJX Companies benefits from the high inflation and interest rate environment because shoppers are still flush but turning more to ... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Retail/Wholesale | |
“Be fearful when others are greedy, and greedy when others are fearful.”
Warren Buffett said it best: Great investing often involves seeking out unloved names that the market has overlooked or undervalued.
While it's tempting to buy popular stocks like NVIDIA (NASDAQ: NVDA) and Tesla... Read the Full Story |
|
Technology | |
After reporting its first quarter 2024 earnings report, shares of Zoom Video Communications Inc. (NASDAQ: ZM) shook markets by initially plummeting as much as 4.6% from their closing price and swiftly rising back to show a 2.5% premium to the day’s end. To put this price action simply, a sig... Read the Full Story |
|
Finance | |
A 5% dip during Tuesday’s session was the latest in a run of red days for Wayfair Inc (NYSE: W) stock. It came as it did in the days after the benchmark S&P 500 index set a fresh all-time high, which will have made it worse for investors.
They’d have been forgiven for thinking at... Read the Full Story |
|
|
Retail/Wholesale | |
Investors looking for worthwhile companies to add to their portfolios should consider a few factors that make up a ‘high-quality’ stock. The company’s product or service and the relative moat around them are among these factors. Moat is a word today’s newer retail investors... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. | | View Today's Stock Pick |
|
Many new investors are surprised...